Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML
Open Access
- 15 September 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 104 (6), 1855-1858
- https://doi.org/10.1182/blood-2004-02-0712
Abstract
The FLT3 receptor is activated by juxtamembrane insertion mutations and by activation loop point mutations in patients with acute myeloid leukemia (AML). In a systematic tyrosine kinase gene exon resequencing study, 21 of 24 FLT3 exons were sequenced in samples from 53 patients with AML, 9 patients with acute lymphoblastic leukemia (ALL), and 3 patients with myelodysplasia samples. Three patients had novel point mutations at residue N841 that resulted in a change to isoleucine in 2 samples and to tyrosine in 1 sample. Introduction of FLT3-N841I cDNA into Ba/F3 cells led to interleukin-3 (IL-3)–independent proliferation, receptor phosphorylation, and constitutive activation of signal transducer and activator of transcription 5 (STAT5) and extracellular regulatory kinase (ERK), suggesting that the N841I mutation confers constitutive activity to the receptor. An FLT3 inhibitor (PKC412) inhibited the growth of Ba/F3-FLT3N841I cells (IC50 10 nM), but not of wild-type Ba/F3 cells cultured with IL-3. PKC412 also reduced tyrosine phosphorylation of the mutant receptor and inhibited STAT5 phosphorylation. Examination of the FLT3 autoinhibited structure showed that N841 is the key residue in a hydrogen-bonding network that likely stabilizes the activation loop. These results suggest that mutations at N841 represent a significant new activating mutation in patients with AML and that patients with such mutations may respond to small-molecule FLT3 inhibitors such as PKC412.Keywords
This publication has 20 references indexed in Scilit:
- FLT3 mutations in childhood acute lymphoblastic leukemiaBlood, 2004
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002
- Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual diseaseBlood, 2002
- PML/RARα and FLT3-ITD induce an APL-like disease in a mouse modelProceedings of the National Academy of Sciences, 2002
- Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapyLeukemia, 2001
- A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutationsBlood, 2001
- Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitorLeukemia, 2001
- Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemiaBritish Journal of Haematology, 2001
- Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignanciesBlood, 2001
- Signaling Through the Hematopoietic Cytokine ReceptorsAnnual Review of Immunology, 1995